"Safety and Efficacy of Brolucizumab™ in Indian Population"

Recalcitrant macular edema can pose serious challenges to the treating physician. It is defined as persistence of with central foveal thickness ≥ 300 μ after at least 3 intravitreal injections [1]. be either due VEGF or NON mediated pathways thereby requiring appropriate therapy [2].This article mainly has its scope focussed upon arm treatment failure. Inadequate dosage drugs, inadequate penetration drugs into sub RPE level sometimes related development ‘Tachyphylaxis’ administered anti drug a challenge for physicians [2]